Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, Lammerts van Bueren J, Chiu C, Doshi P, Pérez-Galán P.

Haematologica. 2019 Jul 11. pii: haematol.2018.211904. doi: 10.3324/haematol.2018.211904. [Epub ahead of print]

2.

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.

Lee-Vergés E, Hanna BS, Yazdanparast H, Rodríguez V, Rodríguez ML, Giró A, Vidal-Crespo A, Rosich L, Amador V, Aymerich M, Villamor N, Delgado J, Lichter P, Pérez-Galán P, López-Guerra M, Campo E, Seiffert M, Colomer D.

Int J Cancer. 2019 Jun 1;144(11):2762-2773. doi: 10.1002/ijc.32010. Epub 2019 Jan 16.

PMID:
30468254
3.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Body S, Esteve-Arenys A, Miloudi H, Recasens-Zorzo C, Tchakarska G, Moros A, Bustany S, Vidal-Crespo A, Rodriguez V, Lavigne R, Com E, Casanova I, Mangues R, Weigert O, Sanjuan-Pla A, Menéndez P, Marcq B, Picquenot JM, Pérez-Galán P, Jardin F, Roué G, Sola B.

Sci Rep. 2017 Oct 24;7(1):13946. doi: 10.1038/s41598-017-14222-1.

4.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Giné E, Navarro A, Beà S, Campo E, López-Guillermo A, Lopez-Guerra M, Roué G, Colomer D, Pérez-Galán P.

Haematologica. 2017 Nov;102(11):e447-e451. doi: 10.3324/haematol.2017.168930. Epub 2017 Aug 24. No abstract available.

5.

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.

Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.

6.

Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).

Matas-Céspedes A, Rodriguez V, Kalko SG, Vidal-Crespo A, Rosich L, Casserras T, Balsas P, Villamor N, Giné E, Campo E, Roué G, López-Guillermo A, Colomer D, Pérez-Galán P.

Clin Cancer Res. 2014 Jul 1;20(13):3458-71. doi: 10.1158/1078-0432.CCR-14-0154. Epub 2014 May 5.

Supplemental Content

Loading ...
Support Center